See more : AutoZone, Inc. (0HJL.L) Income Statement Analysis – Financial Results
Complete financial analysis of 89bio, Inc. (ETNB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 89bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Solar Integrated Roofing Corporation (SIRC) Income Statement Analysis – Financial Results
- Fomento Económico Mexicano, S.A.B. de C.V. (FMX) Income Statement Analysis – Financial Results
- LEG Immobilien SE (LEGIF) Income Statement Analysis – Financial Results
- Pacific West Bank (PWBO) Income Statement Analysis – Financial Results
- SLC Agrícola S.A. (SLCJF) Income Statement Analysis – Financial Results
89bio, Inc. (ETNB)
About 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 273.00K | 240.00K | 79.00K | 60.00K | 17.00K | 6.00K |
| Gross Profit | -273.00K | -240.00K | -79.00K | -60.00K | -17.00K | -6.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 122.23M | 80.80M | 70.33M | 36.20M | 21.35M | 13.68M |
| General & Administrative | 28.97M | 21.45M | 19.41M | 13.16M | 5.29M | 1.48M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.97M | 21.45M | 19.41M | 13.16M | 5.29M | 1.48M |
| Other Expenses | 0.00 | 242.00K | -526.00K | -203.00K | -30.56M | -986.00K |
| Operating Expenses | 151.20M | 102.25M | 89.74M | 49.36M | 26.64M | 15.16M |
| Cost & Expenses | 151.20M | 102.25M | 89.74M | 49.36M | 26.64M | 15.16M |
| Interest Income | 0.00 | 2.16M | 148.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.59M | 1.92M | 674.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 273.00K | 240.00K | 79.00K | 60.00K | 17.00K | 6.00K |
| EBITDA | -134.46M | -99.85M | -90.19M | -49.50M | -57.19M | -16.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -151.20M | 102.25M | -89.74M | -49.36M | -26.64M | -15.16M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 12.88M | 242.00K | -526.00K | -203.00K | -30.56M | -986.00K |
| Income Before Tax | -138.32M | -102.01M | -90.27M | -49.56M | -57.20M | -16.15M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.87M | 19.00K | -147.00K | -59.00K | 218.00K | 28.00K |
| Net Income | -142.19M | -102.03M | -90.12M | -49.50M | -57.42M | -16.18M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.00 | -2.93 | -4.48 | -3.08 | -5.40 | -3.53 |
| EPS Diluted | -2.00 | -2.93 | -4.48 | -3.08 | -5.40 | -3.53 |
| Weighted Avg Shares Out | 71.17M | 34.81M | 20.10M | 16.09M | 10.64M | 4.58M |
| Weighted Avg Shares Out (Dil) | 71.17M | 34.81M | 20.10M | 16.09M | 10.64M | 4.58M |
89bio to Participate in the Leerink Partners Global Biopharma Conference
SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will...
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an...
89BIO (ETNB) Just Overtook the 200-Day Moving Average
After reaching an important support level, 89BIO (ETNB) could be a good stock pick from a technical perspective. ETNB surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
– Plan to initiate the Phase 3 ENLIGHTEN NASH program for non-cirrhotic (F2-F3) and cirrhotic (F4) patients in the first and second quarters of 2024, respectively –
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average
After reaching an important support level, 89BIO (ETNB) could be a good stock pick from a technical perspective. ETNB surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect?
The mean of analysts' price targets for 89BIO (ETNB) points to a 168.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it closed its...
Source: https://incomestatements.info
Category: Stock Reports